智通财经网·2025-08-26 18:00Core Viewpoint - Junshi Biosciences (688180.SH) reported a significant revenue increase of 48.64% year-on-year for the first half of 2025, driven by the sales of commercialized drugs, despite a net loss attributable to shareholders of 413 million yuan [1] Financial Performance - The company achieved a revenue of 1.168 billion yuan, an increase of approximately 382 million yuan compared to the same period last year, reflecting a growth rate of 48.64% [1] - The net loss attributable to shareholders was 413 million yuan, with a basic earnings per share of -0.42 yuan [1] - The diluted earnings per share also reflected a loss, indicating ongoing financial challenges despite revenue growth [1] Sales Performance - The sales revenue of Tuoyi® in the domestic market reached 954 million yuan, representing a year-on-year growth of approximately 42% [1] - The increase in sales revenue from commercialized drugs contributed significantly to the reduction in net loss compared to the previous year [1] Strategic Focus - The company is implementing a "quality improvement and efficiency enhancement" action plan, focusing on R&D projects with competitive advantages and innovation [1] - Efforts are being made to accelerate clinical development, reduce production costs, and improve sales efficiency to further decrease losses [1]